Dementia is a group of brain disorders that cause a decline in cognitive functions like memory and thinking. While some cognitive decline is a natural part of aging, dementia is an extreme version ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

Alzheimer’s disease affects millions of people around the world, slowly damaging memory, thinking, and behavior. For decades, scientists have searched for a way to stop or even slow down this ...

Alzheimer’s disease is one of humanity’s most formidable foes. It affects 10 percent of people over age 65 and kills more people each year than breast cancer and prostate cancer combined. Its effects ...

Discover how AI is reshaping Alzheimer’s and dementia care through early detection, faster clinical trials, and improved ...

A systematic review and meta-analysis of approximately 4.5 million people suggests that how much you move, sit, and sleep ...

As scientists race to develop simple blood tests that could one day act as an early warning system for Alzheimer’s disease by sounding the alarm before memory problems appear, new research shows ...

Nearly 7 million Americans currently live with Alzheimer’s and by 2060, experts say that number could be as high as 14 million. Scientists are trying to find out how one man has been able to stave off ...

Nearly 7 million Americans currently live with Alzheimer's, and by 2060, experts say that number could be as high as 14 million. Scientists are trying to find out why one man has been able to stave ...

As an internal medicine doctor, I used to care for Alzheimer’s patients. Now, at just 60 years old, I am one. My diagnosis is not the future most people hope for — but there is finally a generation of ...

Lewy body dementia is the second-most-common dementia, but it is underrecognized. Recognizing its distinct symptoms can help ...

GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% ...